
Citius Pharmaceuticals Inc – NASDAQ:CTXRW
Citius Pharmaceuticals stock price today
Citius Pharmaceuticals stock price monthly change
Citius Pharmaceuticals stock price quarterly change
Citius Pharmaceuticals stock price yearly change
Citius Pharmaceuticals key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | -0.68 |
EV/Sales | N/A |
EV/EBITDA | 0.86 |
Price/Sales | N/A |
Price/Book | 0.19 |
PEG ratio | 0.02 |
EPS | -0.68 |
Revenue | N/A |
EBITDA | -30.39M |
Income | -30.69M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCitius Pharmaceuticals stock price history
Citius Pharmaceuticals stock forecast
Citius Pharmaceuticals financial statements
Sep 2021 | 0 | -4.96M | |
---|---|---|---|
Dec 2021 | 0 | -9.22M | |
Mar 2022 | 0 | -7.59M | |
Jun 2022 | 0 | -8.91M |
Sep 2021 | 142429059 | 9.64M | 6.77% |
---|---|---|---|
Dec 2021 | 137516076 | 12.95M | 9.42% |
Mar 2022 | 127785970 | 9.59M | 7.5% |
Jun 2022 | 120315795 | 9.97M | 8.29% |
Sep 2021 | -5.59M | -40M | -120.47M |
---|---|---|---|
Dec 2021 | -4.65M | 0 | 95.88K |
Mar 2022 | -9.66M | 0 | 0 |
Jun 2022 | -7.71M | 0 | 178K |
Citius Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Apr 2019 | 2588996 | 0 |
Sep 2019 | 5586594 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | MAZUR LEONARD L director, 10 perc.. | Common Stock | 2,234,700 | $3.45 | $7,709,715 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Warrant to Purchase Common Stock | 2,234,700 | $3.45 | $7,709,715 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Common Stock | 558,597 | $1.15 | $642,387 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Warrant to Purchase Common Stock | 558,597 | $1.15 | $642,387 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Warrant to Purchase Common Stock | 1,165,048 | $3.45 | $4,019,416 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Common Stock | 1,165,048 | $3.45 | $4,019,416 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Warrant to Purchase Common Stock | 129,450 | $1.15 | $148,868 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Common Stock | 129,450 | $1.15 | $148,868 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Common Stock | 3,137,255 | $3.45 | $10,823,530 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Common Stock | 784,314 | $1.15 | $901,961 |
-
What's the price of Citius Pharmaceuticals stock today?
One share of Citius Pharmaceuticals stock can currently be purchased for approximately $0.14.
-
When is Citius Pharmaceuticals's next earnings date?
Unfortunately, Citius Pharmaceuticals's (CTXRW) next earnings date is currently unknown.
-
Does Citius Pharmaceuticals pay dividends?
No, Citius Pharmaceuticals does not pay dividends.
-
What is Citius Pharmaceuticals's stock symbol?
Citius Pharmaceuticals Inc is traded on the NASDAQ under the ticker symbol "CTXRW".
-
What is Citius Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Citius Pharmaceuticals?
Shares of Citius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When Citius Pharmaceuticals went public?
Citius Pharmaceuticals Inc is publicly traded company for more then 8 years since IPO on 3 Aug 2017.
Citius Pharmaceuticals company profile:
NASDAQ
0
Biotechnology
Healthcare
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
,
CIK: 0001506251
:
: